Zhengye Biotechnology Holding Limited

ZYBT Healthcare Drug Manufacturers Specialty & Generic

Zhengye Biotechnology Holding Limited’s revenue for fiscal 2025 (year ended December 2025) was $16.6 million, down 34.8% from fiscal 2024.

1.43 0.07 −4.67%
Market cap
$44.6M
P/E
—
Fwd P/E
—
Dividend yield
—
F-score
2/9
Altman Z
1.47
Beneish M
−3.71
Dividend safety
n/a

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Older periods Jun '24 Dec '24 Jun '25 Dec '25
Other line items

+1 more quarter

Show all line items

In millions of $ except per-share values · columns are period end dates